Recursion Pharmaceuticals
"TechBio" pioneer that runs a scaled phenomics platform — automated cell imaging + ML — to discover drug candidates, now merged with Exscientia.
1. Core Product / Service
Recursion Pharmaceuticals (NASDAQ: RXRX) operates the Recursion OS, a platform that combines automated high-throughput cell imaging ("phenomics"), ML-driven feature extraction, and a proprietary biological dataset to predict drug candidates [1]. Its thesis, branded "TechBio", is that industrialized biological data plus machine learning can industrialize discovery the way "TechBio" differs from "BioTech".
After its November 2024 all-stock merger with Exscientia (~$688M), the combined company added Exscientia's precision chemistry / generative molecular design to Recursion's phenomics, giving it an end-to-end "design → screen" stack [1]. In June 2025 it also released Boltz-2, an open-source biomolecular foundation model built with MIT and NVIDIA [1].
2. Target Users & Pain Points
- Pharma partners (Roche/Genentech, Sanofi) licensing the platform or co-developing programs.
- Its own pipeline — Recursion runs internal oncology and rare-disease programs.
Pain solved: preclinical discovery is slow and failure-prone; Recursion positions industrial-scale data generation + ML to move failure earlier and cheaper (see ai-for-science).
3. Competitive Landscape
| Player | Positioning | Vs. Recursion |
|---|---|---|
| isomorphic-labs | AlphaFold-lineage, Alphabet-funded | Big-tech funded; Recursion is independent/public |
| insilico-medicine | Generative-AI-first biotech (Pharma.AI) | Recursion is phenomics/data-first |
| absci | De novo antibody design + wet lab | Antibody-focused; Recursion broader small-molecule/oncology |
| insitro | ML + causal biology (disease mechanism) | Insitro leans causal-biology discovery; Recursion leans scale |
4. Unique Observations
- Scale over cleverness: Recursion is the purest bet that industrialized wet-lab data generation — not a novel model architecture — is the moat in AI drug discovery; its automated imaging flywheel predates the generative-AI wave.
- "Trading at cash, period, if it weren't for AI": investor commentary this period framed most of Recursion's market value as resting on upcoming clinical readouts, underscoring how far the whole sector's valuation still hangs on proof rather than platform revenue [1].
- Consolidation as survival: the Exscientia merger is the sector's clearest signal that AI-biotech is consolidating around scale and cash runway before any blockbuster exists.
5. Financials / Funding
- IPO: 2021 (Nasdaq: RXRX) [1].
- NVIDIA strategic investment: $50M (July 2023) [1].
- Roche/Genentech: ~$150M upfront (Dec 2021); Sanofi collaboration has generated ~$130M inflows through Q1 2025 [1].
- Merger cash: ~$850M combined at Exscientia close (Nov 2024) [1].
- Q1 2025: revenue $15M; net loss $203M; cash $509M as of Mar 31, 2025 [2].
- 2025 restructuring:
20% workforce cut (160 roles) to extend runway to Q4 2027 [1].
6. People & Relationships
- Co-founder / CEO: Chris Gibson, PhD.
- Exscientia leadership: David Hallett (interim CEO) became CSO post-merger.
- Investors/partners: NVIDIA, Roche/Genentech, Sanofi.
- Peers: isomorphic-labs, insilico-medicine, insitro, absci.
Sources
- [1] Recursion Pharmaceuticals — AI Wiki profile (2026-08-24)
- [2] Nasdaq, "Recursion Reports First Quarter 2025 Financial Results…" (2026-08-24)